Stabilizer for urate oxidase and pegylated conjugate thereof, and pharmaceutical use of stabilizer

Through non-covalent bonding with uric acid oxidase, xanthine significantly improves the stability of uric acid oxidase, solves the problem of reduced efficacy of uric acid oxidase therapy in the prior art, and achieves longer-term effective hyperuricemia and gout treatment effects.

WO2025002334A1PCT designated stage expired Publication Date: 2025-01-02HANGZHOU GRAND BIOLOGIC PHARMA INC +1
View PDF 7 Cites 0 Cited by

Patent Information

Application Number
PCT/CN2024/102323
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-06-28
Filing Date
2024-06-28
Publication Date
2025-01-02

AI Technical Summary

Technical Problem

Due to the heterologous nature of microbial sources, the anti-uridase antibodies in patients' bodies are cleared after repeated infusion, which reduces the efficacy of the drug rapidly, making it difficult to treat hyperuricemia and gout stably in the long-term stable treatment.

Method used

Xanthine is used as a stabilizer and combined with uric acid oxidase. By combining it with non-covalent bonds, the stability of uric acid oxidase is significantly improved and its tetramer stability in the body is enhanced.

Benefits of technology

Xanthine significantly improves the stability and activity of uric acid oxidase, prolongs the efficacy, and can effectively reduce uric acid levels in the blood and joints more long-term, and improves the clinical symptoms of gout and hyperuricemia.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure PCTCN2024102323-FTAPPB-I100001
    Figure PCTCN2024102323-FTAPPB-I100001
  • Figure PCTCN2024102323-FTAPPB-I100002
    Figure PCTCN2024102323-FTAPPB-I100002
  • Figure PCTCN2024102323-FTAPPB-I100003
    Figure PCTCN2024102323-FTAPPB-I100003
Patent Text Reader

Abstract

Provided is a method for improving the stability of urate oxidase. An active ingredient urate oxidase and chemically modified urate oxidase are combined with a stabilizer xanthine by means of non-covalent bonding, to significantly improve the tetramer stability of urate oxidase and chemically modified urate oxidase inside and outside an organism, thereby effectively improving the stability of urate oxidase.
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Urate oxidase

    CN101280293A

  • Two uricases from baccilus fastidious and mutants thereof as well as polyethylene glycol modification and application thereof

    CN101875922A

  • Method for modifying uricase by active polyethylene glycol (PEG) against amino group under protection of competitive inhibitor

    CN103083678A

  • Preparation method of uricase of natural mammals

    CN103756983A

  • Enzymatic determination of uric acid

    JP1988063400A